Vanessa’s Law, formally known as the Protecting Canadians from Unsafe Drugs Act, strengthened Health Canada’s authority to identify and respond to safety risks associated with therapeutic products in Canada. Originally introduced in 2014 for products including drugs and medical devices, key Vanessa’s Law authorities were extended to Natural Health Products (NHPs) in June 2023.
The legislation gives Health Canada stronger post-market oversight and enforcement tools, including the authority to order recalls, require label or packaging changes, compel the disclosure of safety information, and impose significantly higher penalties for non-compliance.
For manufacturers, importers, distributors, licence holders, and other regulated businesses, Vanessa’s Law reinforces an important reality: regulatory compliance does not end when a product reaches the Canadian market. Companies need systems capable of identifying, documenting, investigating, and responding to safety and compliance issues throughout the product lifecycle.
The Protecting Canadians from Unsafe Drugs Act, commonly known as Vanessa’s Law, amended Canada’s Food and Drugs Act to strengthen the regulation of therapeutic products and improve Health Canada’s ability to respond when a serious health risk is identified.
The legislation received Royal Assent in November 2014 and was named in memory of Vanessa Young, the daughter of former Member of Parliament Terence Young.
A central objective of Vanessa’s Law was to strengthen Health Canada’s ability to oversee products after they enter the Canadian market. While products are assessed against applicable regulatory requirements before authorization, new information can emerge once they are used by a much larger population.
Vanessa’s Law provides Health Canada with additional tools to obtain information and intervene when those risks arise.
These authorities initially applied to drugs and medical devices. In June 2023, Bill C-47 amended the Food and Drugs Act and extended key Vanessa’s Law authorities to Natural Health Products. This represented a significant change in the post-market oversight of the Canadian NHP industry and remains an important part of Health Canada’s broader evolution toward more active NHP oversight.
Vanessa’s Law applies to therapeutic products regulated under the Food and Drugs Act. Health Canada identifies therapeutic products within the scope of these authorities as including:
Natural Health Products are an especially important addition to this list. When Vanessa’s Law was originally enacted in 2014, NHPs were excluded from its definition of a therapeutic product. Bill C-47 changed that framework in 2023 by extending key Vanessa’s Law authorities to NHPs.
Health Canada states that while NHPs are generally considered lower-risk products, they are not without risk. Issues such as contamination, undeclared ingredients, inaccurate product information, and other serious compliance problems can create risks for consumers.
The change therefore gives Health Canada stronger tools to intervene when an NHP presents a significant safety concern. Health Canada’s broader movement toward increased NHP post-market oversight has also included expanded GMP inspection activity and other regulatory modernization initiatives.
Vanessa’s Law substantially strengthened Health Canada’s ability to respond to safety concerns involving therapeutic products.
Several of these authorities are particularly important for regulated companies.
Mandatory Product Recalls
Health Canada can order a company to recall a therapeutic product where the Minister believes that the product presents a serious or imminent risk of injury to health.
This is an important distinction from a purely voluntary recall framework. When the statutory threshold is met, Health Canada does not necessarily need to rely on the responsible company voluntarily removing the affected product from the market.
For businesses, this makes effective complaint handling, traceability, distribution records, investigation procedures, and recall processes important components of regulatory readiness.
Label and Packaging Changes
Health Canada may order the holder of a therapeutic product authorization to modify a product label or replace or modify its packaging when the Minister believes that doing so is necessary to prevent injury to health.
New safety information can emerge after a product has already entered the market. Existing warnings, directions, risk information, or other elements of the label may consequently become inadequate.
Companies should therefore treat labels as part of an ongoing compliance program rather than assuming that an authorized or previously compliant label will necessarily remain appropriate indefinitely.
Orders to Provide Information
Vanessa’s Law also strengthens Health Canada’s ability to obtain information when a potential health risk is identified.
Health Canada may order a person to provide information that is within their control where the Minister believes that a therapeutic product may present a serious risk of injury to human health.
This makes documentation and information management particularly important. Companies should be prepared to locate and provide relevant information when requested rather than attempting to reconstruct critical records after an issue arises.
Required Assessments, Tests, and Studies
For therapeutic products other than Natural Health Products, the Food and Drugs Act also permits the Minister, subject to the applicable regulatory conditions, to order the holder of a therapeutic product authorization to assess the product and provide the results.
The Minister may also require an authorization holder to compile information, conduct tests or studies, monitor experience with the product, and provide the resulting information.
These powers are distinct from an order to provide information already within a person’s control. They can require a company to generate new evidence needed to evaluate or manage a potential safety risk.
Mandatory Reporting by Hospitals
Vanessa’s Law also established mandatory reporting requirements for prescribed health care institutions. Under the applicable regulations, hospitals must report serious adverse drug reactions and medical-device incidents to Health Canada within the prescribed timelines.
The current statutory provision expressly excludes Natural Health Products. Health Canada has indicated that regulatory amendments would be required before comparable mandatory hospital-reporting requirements could apply to NHPs.
Disclosure of Confidential Business Information
Vanessa’s Law provides Health Canada with authority to disclose confidential business information in specified circumstances without first obtaining the consent of the person or organization to whom the information relates.
These provisions are intended to allow important health and safety information to be shared where necessary, while the Food and Drugs Act continues to establish conditions governing when such disclosure can occur.
For regulated companies, the key point is that information considered commercially confidential is not necessarily protected from disclosure in every circumstance where significant public health or safety considerations are involved.
Stronger Fines and Penalties
One of the most significant changes introduced through Vanessa’s Law was a substantial increase in the
maximum penalties associated with therapeutic-product offences.
Under the Food and Drugs Act, a person convicted on indictment of an offence involving a therapeutic product may be liable to a fine of up to $5 million, imprisonment for up to two years, or both. Because each day on which a continuing offence is committed constitutes a separate offence, this is sometimes described as a potential penalty of up to $5 million per day.
More serious consequences can apply where a person knowingly makes a false or misleading statement to the Minister, knowingly provides false or misleading information, or knowingly or recklessly causes a serious risk of injury to human health while committing another therapeutic-product offence. On conviction by indictment, these offences may result in a fine in an amount determined by the court, imprisonment for up to five years, or both.
These are maximum criminal penalties imposed following conviction; they are not automatic administrative fines whenever non-compliance is identified.
The expansion of key Vanessa’s Law authorities to NHPs therefore exposed the sector to a significantly stronger enforcement framework than existed previously.
Incorporation by Reference
Vanessa’s Law also introduced broader authority for incorporation by reference.
Incorporation by reference allows certain technical standards, lists, guidelines, or other documents to be incorporated into regulations without reproducing the complete material directly within the regulatory text.
From a regulatory modernization perspective, this can make technical requirements easier to update as science, standards, and regulatory expectations evolve.
For industry, however, it also reinforces the importance of monitoring regulatory documents and incorporated materials rather than relying exclusively on the wording of the regulations themselves.
False or Misleading Information
Section 21.6 of the Food and Drugs Act prohibits knowingly making a false or misleading statement to the Minister, or knowingly providing false or misleading information, in connection with a matter under the Act concerning a therapeutic product.
The word “knowingly” is important: the provision is not automatically triggered by every inadvertent error. Nevertheless, companies should maintain appropriate review and verification controls to ensure that regulatory submissions and responses to Health Canada are accurate, complete, supportable, and appropriately documented.
For the NHP sector, June 22, 2023 was a significant regulatory milestone.
Prior to Bill C-47, Natural Health Products continued to be primarily overseen through the Natural Health Products Regulations without being subject to several of the enforcement authorities established by Vanessa’s Law.
Bill C-47 revised the framework so that key Vanessa’s Law powers apply to NHPs.
Health Canada identified the immediately applicable authorities as its ability to:
Bill C-47 did not make every Vanessa’s Law authority operational for Natural Health Products. The immediately applicable authorities include mandatory recalls, label and packaging orders, information orders, disclosure of confidential business information, higher penalties, incorporation by reference, and the prohibition against knowingly providing false or misleading information to the Minister.
However, the current Food and Drugs Act expressly excludes NHPs from the provisions authorizing mandatory product assessments, tests, studies and monitoring, as well as mandatory reporting by health care institutions. Health Canada has also stated that new or amended regulations would be required before it could impose certain additional requirements on NHPs, including terms and conditions on authorizations, mandatory hospital reporting, required tests or studies, and reassessments.
Businesses should therefore distinguish between the Vanessa’s Law authorities that already apply to NHPs and additional lifecycle authorities that would require further regulatory amendments.
The application of Vanessa’s Law to Natural Health Products remains the subject of active legislative debate.
As of July 2026, private member’s Bill C-224 had completed second reading in the House of Commons and had been referred to the Standing Committee on Health. If enacted in its current form, the bill would amend the definition of “therapeutic product” under the Food and Drugs Act to once again exclude most Natural Health Products. NHPs containing nicotine or its salts and used for nicotine-replacement therapy would remain included.
The bill would therefore reverse the 2023 extension of key Vanessa’s Law authorities to most NHPs, including the application of mandatory recall and label-change powers and the strengthened therapeutic-product penalty provisions. It would not repeal Vanessa’s Law generally or remove these authorities from drugs, medical devices, and other therapeutic products.
Bill C-224 has not become law. The Vanessa’s Law authorities extended to NHPs in 2023 therefore remain in effect unless and until Parliament passes legislation changing the current framework.
One of the most important practical implications of Vanessa’s Law is its emphasis on the entire product lifecycle.
Receiving a product authorization does not eliminate a company’s regulatory responsibilities.
Safety signals can emerge from consumer complaints, adverse reactions, scientific literature, inspections, product testing, manufacturing deviations, supplier changes, or other sources after a product has entered the market.
When new information indicates that a product may pose a risk, Health Canada now has substantial authority to request information and require corrective action.
This makes post-market compliance an important extension of pre-market regulatory strategy.
The practical impact will vary depending on the products and activities involved, but companies operating in regulated therapeutic product sectors should consider several areas of their compliance programs.
Post-market monitoring: Companies should have processes for identifying and escalating potential safety signals, complaints, adverse reactions, quality concerns, and other information that could affect the safety profile of their products.
Documentation: Records should be accurate, accessible, and sufficiently organized to support an investigation or regulatory request.
Recall readiness: Companies should understand how affected products can be identified, traced, and removed from distribution if corrective action becomes necessary.
Labelling controls: Processes should exist for assessing new safety information and implementing label or packaging changes when required.
Quality systems: Manufacturing, importing, packaging, labelling, testing, storage, and distribution controls should support ongoing compliance with the applicable regulatory framework.
Regulatory communications: Information submitted to Health Canada should be accurate, complete, and supported by appropriate records.
For NHP businesses in particular, these considerations should be viewed alongside Health Canada’s broader shift toward more active post-market oversight. Recent initiatives have included NHP GMP inspections, labelling modernization, changes to enforcement authorities, and continuing work to modernize the NHP regulatory framework.
Vanessa’s Law should not be viewed in isolation.
Health Canada has increasingly focused on regulatory oversight across the complete lifecycle of regulated products. Within the NHP sector, this has included stronger enforcement powers, GMP inspection activity, revised labelling requirements, and proposals to modernize licensing and post-market requirements.
More recently, Health Canada’s Red Tape Reduction Review and its 2026–2028 Forward Regulatory Plan has proposed reducing some administrative requirements while maintaining or targeting oversight according to risk. For example, Health Canada has considered more flexible approaches to certain product changes and GMP notifications alongside more targeted post-market safety reporting.
These approaches are not necessarily contradictory.
Reducing administrative burden in lower-risk areas can occur alongside stronger intervention when genuine safety risks emerge. The broader direction is toward regulatory oversight that is more proportionate to risk: potentially less routine administration in some areas, but stronger tools and expectations where health, safety, quality, or serious non-compliance is involved.
Companies should ensure that their compliance systems address the Vanessa’s Law authorities currently applicable to their products, together with their existing obligations under the Food and Drugs Act and applicable regulations.
A practical review may include assessing:
For NHP companies, inspection readiness has become particularly important. Health Canada’s increasing focus on NHP GMP inspections, together with the extension of Vanessa’s Law authorities, means companies should be able to demonstrate compliance rather than simply assume that existing licences are sufficient evidence of it.
Vanessa’s Law reinforces the importance of maintaining regulatory compliance throughout the lifecycle of a therapeutic product.
dicentra supports companies navigating Canadian regulatory requirements for Natural Health Products, drugs, medical devices, and other regulated products. Our regulatory and quality teams can assist with regulatory strategy, product licensing and market authorization, NHP site licensing, GMP compliance, label reviews, post-market requirements, recall readiness, regulatory gap assessments, and responses to Health Canada compliance issues.
For NHP companies in particular, the expansion of Vanessa’s Law should be considered alongside evolving GMP inspection, labelling, licensing, and post-market requirements.
If your organization needs help determining how Vanessa’s Law or other Health Canada requirements apply to your products and operations, contact dicentra today.
Disclaimer: This article is provided for general informational purposes only and should not be considered legal or regulatory advice. Regulatory requirements may vary depending on the product, activity, and circumstances involved.